TESARO (TSRO) Misses Q1 EPS by 28c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to TESARO (TSRO) Misses Q1 EPS by 28c

TESARO Announces First-Quarter 2018 Operating Results

May 3, 2018 4:05 PM EDT

ZEJULA Q1 net sales totaled $49 millionEnrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer data accepted for oral presentations at ASCOInitial data from two TSR-042 (anti-PD-1) GARNET expansion cohorts presented at AACR; regulatory submission for MSI-high tumors planned in 2019

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2018, and provided an update on the Company's commercial... More